Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

13:31 EDT 6th May 2015 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 13,000+

Extremely Relevant

Developing a Vaccine for the Epstein-Barr Virus Could Prevent Up To 200,000 Cancers Globally, Say Experts

A vaccine to prevent infection with a common herpes virus, the Epstein-Barr Virus (EBV), could help prevent up to 200,000 new cancers worldwide per year, say Cancer Research UK experts to mark the 50th anniversary of EBV’s discovery, today

AACR 2015: New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus– speci...

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specif...

Neuromyelitis Optica May Be Linked With Epstein-Barr Virus

Persistent, active replication of Epstein-Barr virus might play a role in neuromyelitis optica (NMO) and also might contribute to the immunological alterations that play a role in the disorder, Japanese researchers say. Reuters Health Information

Researchers shed light on link between diet, Epstein-Barr

A new study is shedding light on the connection between diet and a common childhood disease. Using national health data, the researchers determined children who ate certain types of food or dealt with food insecurity may be more likely to contract th...

Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein–Barr virus as a potential vaccine and diagnostic agent

In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures

Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab

Breakthrough Therapy Designation for EBV-Associated Lymphoproliferative Disease After HCT

The US Food and Drug Administration (FDA) is giving the green light to a new immunotherapy for patients who have rituximab-refractory, Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) following allogeneic hematopoietic cell transplantation (HCT).

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatme...

New therapy from naive cells attacks high-risk viruses in cord blood transplant patients

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and the Texas Children's Hospital have expanded the use of virus-specific cell therapy in cord blood transplant patients to successfully prevent thre...

New therapy from naïve cells attacks high-risk viruses in cord blood transplant patients

Researchers have expanded the use of virus-specific cell therapy in cord blood transplant patients to successfully prevent three of the most problematic post-transplant viruses affecting this group of patients that have yet to be addressed clinically...

Epstein-Barr Viral Infections - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H2 2014 is a new report from GlobalData published on 2014-11-17. This 54-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H2 2014’, provides an overview of the...

New therapy from naïve cells attacks high-risk viruses in cord blood transplant patients

(Baylor College of Medicine) Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and the Texas Children's Hospital have expanded the use of virus-specific cell therapy in cord blood transplant patients...

Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-01-29. This 56-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H1 2015’, provides an over...

Cell Medica raises L50M series B

Cell therapy developer Cell Medica Ltd. (London, U.K.) raised L50 million ($78.2 million) in a series B round led by Imperial Innovations. Invesco Perpetual and Woodford Investment Management also participated.Cell Medica's CMD-003 (Cytorex EBV) is i...

Cell Medica granted Orphan Drug designation for novel cellular therapy

Cell Medica announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s cancer immunotherapy treatment, referred to as CMD-003, under development for Epstein-Barr Virus (EBV) positive non-Hodgkin ...

Atara gains on breakthrough designation

Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $0.92 to $20.48 after its partner, Memorial Sloan Kettering Cancer Center, received breakthrough therapy designation for EBV-CTL to treat rituximab-refractory lymphoproliferative disease associated with...

Orphan designation granted to Cell Medica's cancer drug

Cell Medica's novel immunotherapy CMD-003 received orphan drug status from the FDA for use in patients with Epstein-Barr viru -More- 

Valganciclovir May Curb CMV, EBV in Living Kidney Donors

Antiviral prophylaxis with valganciclovir in living kidney donors may reduce transmission of cytomegalovirus (CMV) and Epstein-Barr virus (EBV), a pilot study suggests. Reuters Health Information

Relevant

Study Shows that DNA of Latent EBV May Cause Cancer; Center for the Biology of Chronic Disease Comments on the Latest Study

DNA of the Epstein Barr Virus is linked to epithelial (surface cell) malignancies and malignant transformation (cancer), according to a study published in the Journal of Pathology on December 11, 2014. (1) CBCD reviews the study and recommends two natural EBV remedies. Rochester, NY (PRWEB) January 18, 2015 “Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disea...

Canadian Ebola vaccine licensed to Merck

Global pharma giant Merck & Co Inc. has bought the worldwide commercial rights to NewLink Genetics Corp’s experimental Ebola virus vaccine rVSV-EBOV. The vaccine platform is based on an attenuated strain of vesicular stomatitis virus that has been modified to express an Ebola virus protein that plays an essential role in establishing virus infection. The [&hellip The post Canadian E...

[Articles] Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses

Many studies on environmental factors associated with multiple sclerosis have caveats casting doubts on their validity. Data from more and better-designed studies are needed to establish robust evidence. A biomarker of Epstein-Barr virus (anti-EBNA I...

[Correspondence] Is Canada patent deal obstructing Ebola vaccine development?

A decade ago, Canadian Government scientists invented a vaccine against Ebola virus (VSV-ZEBOV). That vaccine is based on a live attenuated vesicular stomatitis virus, and has several known advantages over the other vaccine candidates in clinical tri...

Next-gen polio vaccine tackles wild virus emergency

Vaccine technology being developed at The University of Queensland could hold the key to completely eradicating polio by removing live virus from the vaccine production process.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks